NCT07180745View on ClinicalTrials.gov

Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

February 1, 2026

Study Completion Date

March 1, 2026

Conditions
Non-alcoholic Fatty Liver Disease NAFLDNon-alcoholic Steatohepatitis NASH
Interventions
DRUG

Pioglitazone (PIO)

30 mg orally once daily

DRUG

Empagliflozin

10 mg orally once daily

DRUG

Statin (Atorvastatin)

20 mg orally once daily

DRUG

Empagliflozin plus Statin (Atorvastatin)

Orally once daily of each (10 mg, 20 mg respectively)

DRUG

Pioglitazone plus Atorvastatin

Orally once daily of each (30mg and 20mg respectively)

Trial Locations (1)

62727

Teaching hospital of Beni Suef University, Banī Suwayf

All Listed Sponsors
lead

Badr University

OTHER